SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-007377
Filing Date
2022-05-04
Accepted
2022-05-04 16:06:33
Documents
14
Period of Report
2022-05-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fate-20220504.htm   iXBRL 8-K 52738
2 EX-99.1 fate-ex99_1.htm EX-99.1 249456
3 GRAPHIC img158830969_0.jpg GRAPHIC 24087
  Complete submission text file 0000950170-22-007377.txt   469600

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fate-20220504_pre.xml EX-101.PRE 9561
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fate-20220504.xsd EX-101.SCH 2519
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fate-20220504_lab.xml EX-101.LAB 12890
8 EXTRACTED XBRL INSTANCE DOCUMENT fate-20220504_htm.xml XML 4522
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 651311552 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 22891506
SIC: 2836 Biological Products, (No Diagnostic Substances)